Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide series |
| |
Authors: | Green Oluyinka M McKenzie Andrew R Shapiro Adam B Otterbein Ludovic Ni Haihong Patten Arthur Stokes Suzanne Albert Robert Kawatkar Sameer Breed Jason |
| |
Affiliation: | Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA. oluyinka.green@astrazeneca.com |
| |
Abstract: | A novel arylsulfonamide-containing series of compounds represented by 1, discovered by highthroughput screening, inhibit the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). X-ray structure determination confirmed that inhibitor binds at the site occupied by acetyl-CoA, indicating that series is competitive with this substrate. This letter documents our early hit-to-lead evaluation of the chemical series and some of the findings that led to improvement in in-vitro potency against Gram-negative and Gram-positive bacterial isozymes, exemplified by compound 40. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |